The UK government is launching a one-off, two-dose MenB vaccination programme for Year 13 students and those under 25 entering university or residential further education for the first time in autumn 2026. According to the Department of Health and Social Care (DHSC), the initiative aims to curb the risk of meningococcal B disease, which is fatal in approximately 10% of cases and can lead to life-altering disabilities. Eligible individuals will be contacted by the NHS to receive their first dose in July and their second in August.
Why are young adults being targeted for this vaccine?
Young adults starting university are at a statistically higher risk of contracting invasive meningococcal disease due to close-quarters living in halls and social environments. According to the UK Health Security Agency (UKHSA), the relative risk for first-year students is substantially higher than for their peers. Dr. Thomas Waite, Deputy Chief Medical Officer, notes that the programme provides direct protection ahead of the typical October and November peak in meningitis cases. While the vaccine is already part of the routine infant schedule, this targeted rollout addresses recent clusters of the disease, including a significant outbreak in Kent earlier this year.
How does this programme compare to previous health initiatives?
This rollout marks a shift toward rapid, reactive intervention in response to localised outbreaks. While the routine infant vaccination programme has led to a 75% reduction in MenB disease within eligible groups, according to UKHSA data, this new effort specifically targets the “protection gap” for older teenagers. Unlike the ongoing infant programme, this is a one-off measure. Charities like Meningitis Now and the Meningitis Research Foundation have campaigned for years for broader access, framing this as a critical step forward while noting that work remains to protect those already in higher education or younger teenagers.
What are the risks of Meningococcal B disease?
Meningococcal Group B (MenB) accounted for approximately 83% of all invasive meningococcal disease (IMD) cases in England during the 2024/25 period, according to UKHSA. The bacteria can spread through intimate contact, such as kissing, sharing drinks, or using shared vapes. The infection is life-threatening and can cause permanent damage, including hearing loss, brain damage, and amputations. Because the disease progresses rapidly, healthcare officials are prioritising this summer window to ensure students have immunity before the academic term begins.
The UKHSA reported 313 confirmed cases of MenB in England during the 2024/25 period. Despite these numbers, the MenB vaccine has an established safety record and has been used safely in the NHS infant schedule for years.
Frequently Asked Questions
Who is eligible for the free MenB vaccine?
The offer is open to students completing Year 13 in summer 2026 (born between 1 September 2007 and 31 August 2008) and anyone under 25 starting university or residential further education for the first time this autumn.
How do I book my appointment?
Eligible students will be contacted via the NHS App, text, email, or letter. According to NHS England, those starting university for the first time can book appointments directly with participating community pharmacies starting in mid-July.
Are post-graduate students covered by this scheme?
No. The current one-off programme is specifically for those entering university or residential further education for the first time. Post-graduates or those entering their second year or later are not included in this offer.
What if I miss one of the two doses?
Two doses are essential for maximum protection. The NHS recommends receiving the first dose in July and the second in August, with at least four weeks between them to ensure the immune system develops the necessary response.
Are you or a family member heading to university this autumn? Check your NHS App or local pharmacy listings in mid-July to confirm your eligibility. For more information on meningitis symptoms and prevention, visit the Meningitis Now or Meningitis Research Foundation websites.
